Reports Q1 revenue $13.47M, consensus $13.37M. “Augmedix delivered in-line first quarter performance, with 40% revenue growth, 143% net revenue retention and 47.1% gross margins,” commented Manny Krakaris, Augmedix CEO. “We are confident about our positioning within the medical documentation market, and expect to report continued growth throughout the rest of the year. It is now clear, however, that health systems are proceeding methodically while they develop a better understanding of the capabilities of AI products.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUGX:
- Augmedix Inc (AUGX) Q1 Earnings Cheat Sheet
- Augmedix to Participate in Upcoming Investor Conferences in May and June 2024
- Augmedix announces general availability of Augmedix Go
- Augmedix upgraded to Outperform from In Line at Evercore ISI
- Augmedix Integrates with Andor Health to Revolutionize Ambient Clinical Documentation for Ambulatory Virtual Care